Search

Fate Therapeutics Inc

Затворен

СекторЗдравеопазване

2.54 2.01

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.45

Максимум

2.63

Ключови измерители

By Trading Economics

Приходи

1.2M

-31M

Продажби

-70K

1.3M

EPS

-0.26

Марж на печалбата

-2,402.848

Служители

161

EBITDA

14M

-28M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+101.54% upside

Дивиденти

By Acuity

Следващи печалби

10.08.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

38M

291M

Предишно отваряне

0.53

Предишно затваряне

2.54

Настроения в новините

By Acuity

14%

86%

24 / 340 Класиране в Healthcare

Fate Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.08.2026 г., 19:56 ч. UTC

Fate Therapeutics shares are higher amid positive market sentiment and falling oil prices, despite some volatility during Wednesday's trading session.

4.08.2026 г., 20:07 ч. UTC

News
Correlated Moves

Fate Therapeutics is gaining as it announces employee inducement awards, including stock options at $2.45 per share. Shares rebounded after an earlier pullback.

3.08.2026 г., 23:01 ч. UTC

News

Fate Therapeutics Inc. shares are lower in after-market trading, despite stronger growth in the manufacturing sector and recent employee inducement awards.

29.07.2026 г., 19:19 ч. UTC

Fate Therapeutics is trading higher amid positive market momentum ahead of the Federal Reserve's monetary policy announcement, despite lingering inflation concerns.

28.07.2026 г., 16:06 ч. UTC

Fate Therapeutics shares are lower amid broader market weakness and investor caution ahead of key earnings reports and the Federal Reserve's interest rate decision.

27.07.2026 г., 21:02 ч. UTC

Fate Therapeutics shares are higher in after-market hours, despite no specific news. Broader market sentiment is improving with rising European equity indices.

24.07.2026 г., 19:07 ч. UTC

Correlated Moves

Fate Therapeutics shares are lower, pressured by a notable decline in first-quarter results and broader market sentiment. They remain below the 20-day moving average.

23.07.2026 г., 21:11 ч. UTC

Fate Therapeutics Inc. shares are higher in after-market hours, reflecting broader market gains. No specific company news has been identified to explain this increase.

22.07.2026 г., 23:46 ч. UTC

Fate Therapeutics Inc shares are higher in after-market trading, reflecting a modest gain since Wednesday's close, despite no specific news identified.

20.07.2026 г., 18:26 ч. UTC

Fate Therapeutics Inc. shares are effectively unchanged as trading remains flat. The stock has seen strong performance over the past month, nearing its recent highs.

Сравнение с други в отрасъла

Ценова промяна

Fate Therapeutics Inc Прогноза

Ценова цел

By TipRanks

101.54% нагоре

12-месечна прогноза

Среден 5.24 USD  101.54%

Висок 8 USD

Нисък 2.2 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Fate Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

9 ratings

5

Купи

4

Задържане

0

Продай

Настроение

By Acuity

24 / 340 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
help-icon Live chat